Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01260948 · ClinicalTrials.gov registry record · Phase 1
10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01260948: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT01260948 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01260948, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study investigated the relative bioavailability (rate and extend of absorption) of Donepezil Hydrochloride Orally Disintegrating Tablets, 10 mg by Teva Pharmaceuticals, USA with that of Aricept® Orally Disintegrating Tablets, Manufactured and Marketed by Eisai Inc., following a single oral dose (1 x 10 mg orally disintegrating tablet) in healthy adult subjects administered under non-fasting conditions.
Interventions
- DRUG Donepezil Hydrochloride
- DRUG Aricept®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2006-04 |
| Est. Completion | 2006-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01260948
The ClinicalTrials.gov registry entry for NCT01260948 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Donepezil Hydrochloride is the first listed.
NCT01260948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01260948 about?
NCT01260948 is a clinical study titled "10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions". This study investigated the relative bioavailability (rate and extend of absorption) of Donepezil Hydrochloride Orally Disintegrating Tablets, 10 mg by Teva Pharmaceuticals, USA with that of Aricept® Orally Disintegrating Tablets, Manufactured and Marketed by Eisai Inc., following a single oral dose...
What is the current status of trial NCT01260948?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2006-04. Estimated completion is 2006-05.
What interventions are being tested in trial NCT01260948?
The interventions under investigation include: Donepezil Hydrochloride (DRUG), Aricept® (DRUG).
Who is sponsoring clinical trial NCT01260948?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.